For some, this may be a bit too hands-off
This trial focused on people with obesity and knee osteoarthritis
The menstrual changes are downstream effects of metabolic changes (insulin sensitivity, weight loss), not direct hormonal interference
The starting dose is 0.1 mg (50 l) three times daily and is injected subcutaneously 5 minutes before meals
Jojima T, Uchida K, Akimoto K, Tomotsune T, Yanagi K, Iijima T, Suzuki K, Kasai K, Aso Y: Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice
Additional indications under investigation include type 2 diabetes management and metabolic dysfunction-associated steatohepatitis